Background: Ovarian hyper stimulation syndrome (OHSS) is an iatrogenic and potentially life-threatening disease process, which may occur in healthy young women undergoing control ovarian hyper stimulation. Objective: To assess the effect of Cabergoline on implantation when used to prevent or treat ovarian hyper stimulation syndrome. Patients and Methods: This study was conducted at IVF Unit, Al-Hussein Hospital, Al-Azhar University from March 2015 to March 2020 on 100 women with high risk evidence to ovarian hyper stimulation syndrome with ovulation induction divided in two equal groups: Group I: 50 started on tablet cabergoline 0.5 mg/day from the day of ovulation trigger and continued until the next 8 days and Group II: 50 did not take cabergoline. This study was carried on private center. All of the patients were followed up by pregnancy test in serum (BHCG titre) and examination by transvaginal U/S at 6 week of gestation. Results: The study showed no statistically significant difference between Group I and Group II: to primary or secondary infertility. However, there was a statistically significant increase on positive group I compared to group II according to fetal heart pulsation. Conclusion: Cabergoline reduced the incidence of OHSS in ICSI cycles. In women at high risk of OHSS, cabergoline can be administered as soon as the hCG injection to prevent early OHSS. Higher rates of clinical and chemical pregnancy were observed after cabergoline administration in ICSI cycles.